Kyntra Bio Amends Revenue-Interest Financing, Cuts Payment Obligation by $60M

What Happened
Kyntra Bio, Inc. announced on August 31, 2026 that it entered into an amended and restated Revenue Interest Financing Agreement (A&R RIFA) with NQ Project Phoebus, L.P., reducing the maximum aggregate payments under the agreement from $125 million to $65 million — a $60 million reduction of future payment obligations. Upon signing, Kyntra paid a $42.6 million accelerated upfront payment, bringing total payments made to NQ Project Phoebus to $50 million (a full return of NQ Project Phoebus’s invested capital). Kyntra now has $15 million of remaining payment obligations tied to future EVRENZO™ (roxadustat) royalties.

Key Details

• Counterparty: NQ Project Phoebus, L.P.; original RIFA dated November 4, 2022, amended August 31, 2026.
• Reduced cap: Maximum aggregate payments lowered from $125M to $65M (net $60M reduction).
• Cash paid: $42.6M accelerated upfront on signature; total paid to date = $50M (return of invested capital).
• Remaining obligation: $15M cap, paid via 50% of EVRENZO royalties Kyntra receives from Astellas Pharma for sales in Europe and all Astellas territories excluding Japan, paid quarterly.
• Japan royalties: No longer subject to royalty payments under the A&R RIFA and related IP/collateral for Japan royalties are released.
• Optionality: Kyntra may prepay or repay the $15M cap at any time; once the cap is reached the A&R RIFA expires and Kyntra retains all subsequent royalties.

Why It Matters
This amendment materially reduces Kyntra Bio’s future cash obligations (by $60M) while accelerating a near-term cash outflow ($42.6M) to return the financier’s capital. The company retains upside after the new $15M cap is met (all subsequent EVRENZO royalties from Astellas territories revert to Kyntra), and Japan revenue is freed from the financing arrangement immediately. For investors, the deal changes future royalty cash flows and collateral structure but does not represent an equity dilution, merger, or asset sale. The full A&R RIFA will be filed as an exhibit in Kyntra’s Form 10-Q for the quarter ending September 30, 2026.